People: Mesoblast Ltd (MSB.AX)
Dr. Eric A. Rose, M.D., has been Non-Executive Independent Director of Mesoblast Ltd., Eric Rose is a world leader in cardiovascular medicine. He is currently Chairman and CEO of SIGA Technologies and Executive Vice President, Life Sciences, at MacAndrews & Forbes, Inc., the holding company of Ronald O. Perelman. From 2008 through 2012, Dr Rose served as the Edmond A. Guggenheim Professor and Chairman of the Department of Health Evidence and Policy at the Mount Sinai School of Medicine, which has an extensive portfolio of research focused on evaluation of complex medical technologies in cardiovascular disease, cancer, diabetes mellitus, and neurologic disease. From 1994 through 2007, Dr Rose served as Chairman of the Department of Surgery and Surgeonin- Chief of the Columbia Presbyterian Center of New York Presbyterian Hospital. From 1982 to 1992, he led the Columbia Presbyterian heart transplantation program, during which time it became the most active program in the United States. Dr Rose pioneered heart transplantation in children, performing the first successful pediatric heart transplant in 1984. He has investigated many alternatives to heart transplantation, including cross species transplantation and man-made heart pumps and is also Chairman of the Board of Circulite, Inc., a developer of advanced left ventricular assist devices. Dr Rose has authored or co-authored more than 300 scientific publications and has received more than $25 million in National Institutes of Health support for his research. He has been Director of SIGA Technologies (since 2001) and was Director of ABIOMED (2007 to 2012).
|Total Annual Compensation, AUD||142,167|
|Restricted Stock Awards, AUD||--|
|Long-Term Incentive Plans, AUD||--|
|All Other, AUD||--|
|Fiscal Year Total, AUD||142,167|